ADCK2 and non-small cell lung carcinoma: In NSCLC cells, downregulating ADCK2 levels through shRNA or CRISPR/Cas9 KO inhibited NSCLC cell viability, proliferation, and mobility, induced apoptosis, disrupted mitochondrial functions, and downregulated Akt-mTOR signaling [21].